[1]沈明强,吴冠会,董晓峰,等.急性脑梗死联合抗栓治疗的疗效分析[J].卒中与神经疾病杂志,2017,24(03):223-225+233.[doi:10.3969/j.issn.1007-0478.2017.03.013]
　Shen Mingqiang,Wu Guanhui,Dong Xiaofeng,et al.The clinical study on the efficacy of combined antithrombotic therapy of acute cerebral infarction[J].Stroke and Nervous Diseases,2017,24(03):223-225+233.[doi:10.3969/j.issn.1007-0478.2017.03.013]
点击复制

急性脑梗死联合抗栓治疗的疗效分析()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第24卷
期数:
2017年03期
页码:
223-225+233
栏目:
论 著
出版日期:
2017-06-26

文章信息/Info

Title:
The clinical study on the efficacy of combined antithrombotic therapy of acute cerebral infarction
文章编号:
1007-0478(2017)03-0223-04
作者:
沈明强; 吴冠会; 董晓峰; 冯红选
215002 苏州,南京医科大学附属苏州医院神经内科
Author(s):
Shen Mingqiang; Wu Guanhui; Dong Xiaofeng; et al.
Department Of Neurology, Suzhou Hospital Affiliated Nanjing Medical University,Suzhou 215002
关键词:
脑梗死 阿加曲班 抗凝治疗 联合抗栓治疗 预后
Keywords:
Cerebral infarction Argatroban Injection Anticoagulation therapy Combined antithrombotic therapy Prognosis
分类号:
R743.32
DOI:
10.3969/j.issn.1007-0478.2017.03.013
摘要:
目的 评价急性脑梗死联合抗栓治疗的疗效。方法 收集2014年1月～2015年10月本院神经内科收治急性脑梗死病例227例,发病48 h内; 使用阿司匹林治疗的患者48例为阿司匹林组; 早期使用阿加曲班的患者72例为阿加曲班组; 早期联合使用阿加曲班和阿司匹林的患者107例为联合组; 3组均采用他汀类药物调脂、血压血糖控制等治疗; 阿加曲班注射液使用方法为首日和次日以60 mg剂量+生理盐水500 mL于24 h内滴完,自第3 d起用药剂量调整为10 mg+生理盐水250 mL分早晚2次滴注,每次于3 h内滴完,连续5 d; 使用NIHSS评分和mRS评分对两组患者在治疗前、疾病高峰时、14 d、6月进行评定,比较3组疗效。结果 阿司匹林组、阿加曲班组和联合组入院基线资料比较,性别构成、年龄、入院血压、入院血糖、LDL-C、入院初始NIHSS评分比较无显著差异(P>0.05),具有可比性。3组患者14 d时NIHSS评分较峰值NIHSS评分均有显著下降; 3组NIHSS评分改善度有显著差异,联合组显著大于其余2组,而阿司匹林组和阿加曲班组比较无明显差异(F=15.379,P<0.05); 3组患者病程6月时mRS比较联合组要显著低于阿司匹林组,其余组间比较无明显差异(F=2.376,P>0.05)。结论 急性脑梗死患者阿加曲班抗凝治疗有效,联合抗栓治疗显示具有更好的效果和预后。
Abstract:
ObjectiveTo evaluate the efficacy of combined antithrombotic therapy of acute cerebral infarction.Methods 227 patients with acute cerebral infarction were collected within 48 hours after onset from January 2014 to October 2015, the patients were divided into the aspirin group(the aspirin therapy,48 cases), the argatroban group(the argatroban therapy, 72 cases), the combined antithrombotic group(the argatroban and aspirin therapy, 107 cases). Three groups were treated by the basic therapy such as stains lipid lowing, blood pressure and blood sugar controlling.the argatroban group and combined antithrombotic group were treated with venous argatroban in 1st week. It was 60 mg/d within the first 2 days and 24 h continuous drip.From the beginning of the 3rd day, the dosage was changed to 10 mg each time, twice a day for 5 days.The degree of neurological deficit was compared by the National Institutes of Health Stroke Scale(NIHSS)Scoring and the rehabilitation condition was evaluated by modified Rankin Scale(mRS)scoring among 3 groups before treatment, at the peak time of disease course and 14 d, 6 months after treatment respectively.Results There was no significant difference in sex composition, age, blood pressure, blood glucose, LDL-C, admission NIHSS score among three groups. 14d NIHSS score of each group was significantly lower than that at the peak time of disease course. There were significant differences at the degree of improvement in NIHSS scores among the three groups. NIHSS score improvement was significantly higher in the combined antithrombotic group than those in the other two groups, while there was no difference between the aspirin group and the argatroban group(F=15.379, P<0.05). mRS score was significantly lower in the combined antithrombotic group 6 months after treatment than that in the aspirin group, while there was no difference among the other groups(F=2.376, P>0.05).Conclusion Argatroban anticoagulant treatment is effective on the patients with acute cerebral infarction within 48 hours after onset.The combined antithrombotic treatment showed better effect and prognosis.

参考文献/References:

[1] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊疗指南撰写组.中国急性缺血性脑卒中诊疗指南2010[J].中华神经科杂志,2010,43(2):146-153.
[2] Field TS,Benavente OR.Current status of antiplatelet agents to prevent stroke[J].Curr Neurol Neurosci Rep,2011,11(1):6-14.
[3] 付海龙,吕晓红.进展性缺血性脑卒中诊断与相关因素的研究[J].中风与神经疾病杂志,2008,25(1):123-125.
[4] 王振义,李家增,阮长耿.血栓与止血基础理论与临床[M].3版.上海:上海科学技术出版社,2004:102-110.
[5] 田成林,蒲传强.抗凝治疗在缺血性脑血管病防治中的应用[J].中华医学杂志,2004,84(14):1231-1232.
[6] Tanaka KA,Szlam F,Katori N,et al.The effects of argatroban on thrombin Generation and hemostatic activation in vitro[J].Anesth Analg,2004,99(5):1283-1289.
[7] Escolar G,Bozzo J,Maragall S.Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions[J].Drugs of Today,2006,42(4):223-236.
[8] Chen B,Friedman B,Whitney MA,et al.Thrombin activity associated with neuronal damage during acute focal ischemia[J].J Neurosci,2012,32(22):7622-7631.
[9] Chen B,Cheng Q,Yang K,et al.Thrombin mediates severe neurovascular injury during ischemia[J].Stroke,2010,41(10):2348-2352.
[10] De La Rosa X,Cervera A,Kristoffersen AK,et al.Mannose-Binding lectin promotes local microvascular thrombosis after transient brain ischemia in mice[J].Stroke,2014,45(5):1453-1459.
[11] Ishibashi H,Koide M,Obara S,et al.High-dose Argatroban Therapy for Stroke: Novel Treatment for Delayed Treatment and the Recanalization Mechanism[J].Journal of Stroke & Cerebrovascular Diseases,2013,22(5):656-660.
[12] Lamonte MP,Brown PM,Hursting MJ.Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy[J].Crit Care Med,2004,32(4):976-980.
[13] 任丽,吴伟,赵伟,等.阿加曲班治疗进展性脑梗死的有效性与安全性[J].中华神经科杂志,2013,46(8):551-554.
[14] Jang IK,Lewis BE,Matthai WJ,et al.Argatroban anti-coagulation in conjunction with glycoproteinⅡb/Ⅲa inhibition in patients undergoing percutaneous coronary intervention:an open-label nonrandomized pilot study[J].J Thromb Thrombolysis,2004,18(1):31-37.
[15] 高志强,张鹏,戴瑛,等.联合抗栓治疗急性缺血性脑卒中的近期疗效和安全性[J].南京医科大学学报:自然科学版,2015,35(8):1152-1154.
[16] 李静,张微微,李莹.阿加曲班对急性脑梗死患者血小板功能的影响[J].中华老年心脑血管病杂志,2011,13(6):541-543.

更新日期/Last Update: 2017-06-20